[go: up one dir, main page]

WO2013094720A1 - Composition présentant une activité promotrice de l'adhésion cellulaire - Google Patents

Composition présentant une activité promotrice de l'adhésion cellulaire Download PDF

Info

Publication number
WO2013094720A1
WO2013094720A1 PCT/JP2012/083196 JP2012083196W WO2013094720A1 WO 2013094720 A1 WO2013094720 A1 WO 2013094720A1 JP 2012083196 W JP2012083196 W JP 2012083196W WO 2013094720 A1 WO2013094720 A1 WO 2013094720A1
Authority
WO
WIPO (PCT)
Prior art keywords
asp
acid
peptide
composition
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/083196
Other languages
English (en)
Japanese (ja)
Inventor
陽子 水垂
正通 阿部
益徳 熊澤
康助 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rohto Pharmaceutical Co Ltd
Original Assignee
Rohto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rohto Pharmaceutical Co Ltd filed Critical Rohto Pharmaceutical Co Ltd
Publication of WO2013094720A1 publication Critical patent/WO2013094720A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a composition for promoting adhesion between cells and collagen, and an invention related thereto.
  • fibroblasts adhere to collagen in the extracellular matrix, strengthening and stabilizing the lattice-like three-dimensional structure of collagen fiber bundles, and strengthening and elasticity of the skin Is one of the reasons for keeping It has been found that when the fibroblast adherence ability to collagen is reduced due to aging or the like, skin elasticity and elasticity are reduced. Furthermore, it is known that fibroblasts themselves become dull in their function (for example, production of various factors) unless they adhere to collagen fibers and grasp the scaffold. For the above reasons, a component that promotes adhesion between fibroblasts and collagen has been searched.
  • Patent Document 1 peptides having a specific sequence (Patent Document 1) and the like have been known as materials for promoting adhesion between skin cells and collagen.
  • the present invention has been made in view of the above prior art, and an object thereof is to provide a useful novel composition capable of highly promoting adhesion between cells and collagen.
  • the present inventors have highly promoted adhesion between cells and collagen by using a combination of short-chain peptides having specific amino acid sequences and vitamins. As a result, the present invention has been completed.
  • the present invention provides the following.
  • the peptide of component (A) is Asp-Leu-Asp-Val-Phe (SEQ ID NO: 2), Arg-Asp-Leu-Asp-Val (SEQ ID NO: 3), Arg-Asp-Leu-Asp
  • the vitamin (B) component is at least one selected from the group consisting of vitamin A, vitamin E, vitamin C, pyrroloquinoline quinones, and vitamin-like agents, [1] Or the composition of [2].
  • component vitamins are retinol palmitate, retinol propionate, retinol linoleate, retinol acetate, retinol, hydrogenated retinol, tocopheryl retinoic acid, tocopherol acetate, tocopherol phosphate, tocopherol phosphate, nicotinic acid Tocopherol, tocopherol succinate, (linoleic / oleic acid) tocopherol, tocopherol, (ascorbyl / tocopheryl) potassium phosphate, tocotrienol, ascorbic acid, 2-O-ethylascorbic acid, 3-O-ethylascorbic acid, 3-O -Cetyl ascorbic acid, tetrahexyldecyl ascorbate, methylsilanol ascorbate, sulfuric acid ascorbate, ascorbyl glucoside, ascorbyl
  • composition according to any one of [1] to [6], which is used for tightening the skin.
  • composition according to any one of [1] to [7], which is used to promote adhesion between cells and collagen.
  • the present invention provides a useful novel composition that can effectively promote the adhesion of cells to collagen. Therefore, according to the present invention, it is possible to effectively prevent a decrease in the adhesion ability between cells (particularly fibroblasts) and collagen caused by aging, etc., and to enhance the binding between fibroblasts and extracellular matrix, There is provided a novel composition that can be beneficially used in practice to increase the tensile strength of the skin, tighten the dermis, improve skin wrinkles and talmi, and restore skin firmness and elasticity.
  • composition of the present invention comprises (A) a peptide comprising the amino acid sequence of the following formula (I): Xaa 1 -Asp-Leu-Asp-Val-Xaa 2 (SEQ ID NO: 1), or a derivative thereof, or a salt thereof. And (B) vitamins.
  • (A) component Peptides blended as the component (A) in the composition of the present invention have the following formula (I): Xaa 1 -Asp-Leu-Asp-Val-Xaa 2 (one letter abbreviation: X 1 DLDVX 2 , SEQ ID NO: 1) Or a derivative thereof, or a salt thereof.
  • Xaa 1 and Xaa 2 (one letter abbreviation: X 1 and X 2 ) in SEQ ID NO: 1 may or may not be present, and when present, each independently represents an arbitrary amino acid.
  • the amino acid is preferably an ⁇ -amino acid, more preferably a genetically encoded ⁇ -amino acid.
  • Xaa 1 and Xaa 2 are naturally occurring Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp Is preferably an ⁇ -amino acid arbitrarily selected from the group consisting of Tyr, Lys and Val, more preferably an ⁇ -amino acid which is Arg or Phe, Xaa 1 is Arg, and Xaa 2 is Phe Is particularly preferred.
  • Xaa 1 and Xaa 2 may or may not be present, but it is preferable that at least one of Xaa 1 and Xaa 2 is present.
  • the peptide used in the present invention is Asp-Leu-Asp-Val-Phe (one letter abbreviation: DLDVF, SEQ ID NO: 2), Arg-Asp-Leu-Asp-Val (one letter abbreviation: RDLDV, SEQ ID NO: 3), Arg-Asp-Leu-Asp-Val-Phe (one letter abbreviation: RDLDVF, SEQ ID NO: 4), or Asp-Leu-Asp -Val (one letter abbreviation: DLDV, SEQ ID NO: 5), preferably Asp-Leu-Asp-Val-Phe (one letter abbreviation: DLDVF, SEQ ID NO: 2), or Arg-Asp-Leu-Asp-Val (One letter abbreviation: RDLDV, SEQ ID NO: 3) is particularly preferable.
  • the “peptide derivative” means, for example, acetylation, palmitoylation, myristylation, amidation, acrylation, dansylation, biotinylation, phosphorylation, succinylation, anilideation, benzyloxylation of peptides.
  • salt refers to any pharmacologically acceptable salt (including inorganic salts and organic salts) of a peptide or a derivative thereof, such as a sodium salt or potassium of a peptide or a derivative thereof.
  • Salt calcium salt, magnesium salt, ammonium salt, hydrochloride, sulfate, nitrate, organic acid salt (acetate, trifluoroacetate, citrate, maleate, malate, oxalate, lactate, Succinate, fumarate, propionate, formate, benzoate, picrate, benzenesulfonate, etc.), preferably ammonium salts, hydrochlorides, sulfates, acetates or tris Fluoroacetate, more preferably ammonium salt, acetate or trifluoroacetate.
  • the peptide or its derivative used in the present invention or a salt thereof may be a hydrate or an anhydride.
  • the solvate or non-solvate may be sufficient as the peptide used in this invention, its derivative (s), or those salts.
  • the peptide used in the present invention can be prepared by a method known in the art.
  • the peptide used in the present invention may be synthesized by a chemical synthesis method (for example, a solid phase method (eg, Fmoc method), a liquid phase method, etc.), or may be produced by a method such as recombinant expression. Good.
  • the amino acid constituting the peptide used in the present invention may be L-form or D-form, but is preferably L-form.
  • the peptide used in the present invention may be prepared by cutting out a peptide comprising the target amino acid sequence from the amino acid sequence of the protein containing the target amino acid sequence by a known means such as protease treatment.
  • a person skilled in the art can appropriately select an appropriate protease in order to cut out a peptide comprising the target amino acid sequence from the amino acid sequence of the protein containing the target amino acid sequence in consideration of the sequence specificity of the protease.
  • the reaction conditions used when the protein is hydrolyzed with a protease are not particularly limited, and can be appropriately selected by those skilled in the art according to common technical knowledge.
  • the target peptide can be purified by purification by means known in the art, if necessary.
  • a peptide obtained by hydrolyzing a natural protein with a protease is advantageous from the viewpoint of cost as compared with the case of producing by a chemical synthesis method. Furthermore, it is considered that a peptide obtained by hydrolyzing a natural protein with a protease is safer for a living body. Therefore, the peptide thus obtained can be suitably used for internal preparations, foods, cosmetics for sensitive skin, feeds, and the like that require higher safety for application to living bodies.
  • the food includes all foods and drinks including beverages.
  • the peptide derivative used in the present invention can be easily prepared by a person skilled in the art by any method known in the art.
  • the salt of the peptide used in the present invention can also be easily prepared by those skilled in the art by any method known in the art.
  • composition of the present invention a peptide selected from the peptides having the above specific sequence or a derivative thereof, or a salt thereof may be used alone or in any combination of two or more. May be used.
  • any of the peptide having the specific sequence described above or a derivative thereof, or a salt thereof can be used.
  • a salt is used, and a peptide is particularly preferably used.
  • the amount of the component (A) to be blended in the composition of the present invention is not particularly limited as long as the effects of the present invention can be obtained, but is usually about 0.00000001 to 80% by weight (w / w)% with respect to the entire composition, Preferably, it is about 0.000001 to 70% by weight (w / w)%.
  • the blending amount may be small, for example, about 0.00000001 to 10 w / w%, preferably 0.000001 to 5 w / w%, more preferably 0.00001 to 1 w / w.
  • a sufficient effect of the present invention can be obtained even when the amount is w%, more preferably 0.00001 to 0.1 w / w%.
  • (B) component In the composition of the present invention, vitamins are further blended as the component (B).
  • Vitamins are not particularly limited as long as they are pharmaceutically or physiologically acceptable.
  • vitamin A you may mix
  • the vitamin A oil is a fatty oil obtained from a tissue of a marine animal (liver, pyloric appendix, etc.) containing vitamin A, or a fatty oil or a concentrate thereof, or a fatty acid ester of vitamin A, as appropriate. It is well known as an addition.
  • one of these vitamins may be used alone, or two or more may be used in any combination.
  • vitamin A and vitamin E are preferable from the viewpoint that it can exert an action of promoting adhesion between cells and collagen more effectively together with component (A).
  • Vitamin C pyrroloquinoline quinones, or vitamin-like agents.
  • the component (B) is retinol palmitate, retinol propionate, retinol linoleate, retinol acetate, retinol, hydrogenated retinol, tocopheryl retinoic acid, tocopherol acetate, tocopherol phosphate, tocopherol linoleate, tocopherol nicotinate, Tocopherol succinate, (linoleic acid / oleic acid) tocopherol, tocopherol, (ascorbyl / tocopheryl) potassium phosphate, tocotrienol, ascorbic acid, 2-O-ethylascorbic acid, 3-O-ethylascorbic acid, 3-O-cetyl Ascorbic acid, tetrahexyldecyl ascorbate, methylsilanol ascorbate, sulfuric acid ascorbate, ascorbyl glucoside, ascorbyl
  • Examples of the salt include sodium salt, potassium salt, calcium salt, magnesium salt, zinc salt, chitosan salt, etc.
  • Specific examples include tocopherol phosphate disodium, disodium ascorbate sulfate, calcium ascorbate, ascorbine.
  • Examples include magnesium acid, sodium ascorbate, zinc ascorbate, chitosan ascorbic acid, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, trisodium ascorbyl phosphate, and disodium pyrroloquinoline quinone.
  • retinol palmitate preferably retinol palmitate, retinol, tocopherol acetate, tocopherol nicotinate, ⁇ tocopherol, ascorbic acid, 3-O-ethylascorbic acid, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, pyrroloquinoline quinone, ⁇ -lipoic acid or coenzyme Q10 is used.
  • the amount of component (B) to be blended in the composition of the present invention is not particularly limited as long as the effects of the present invention can be obtained, but is usually about 0.000001 to 70% by weight (w / w)% with respect to the entire composition. It is good to do.
  • the blending amount may be small, for example, 0.000001 to 5 w / w%, more preferably 0.00001 to 1 w / w%, still more preferably 0.00001 to Even if it is 0.3 w / w%, sufficient effects of the present invention can be obtained.
  • each vitamin will be described in detail.
  • the amount is preferably about 0.00001 to 70% by weight (w / w) based on the entire composition.
  • the blending amount may be small, for example, 0.00001 to 5 w / w%, preferably 0.00005 to 3 w / w%, more preferably 0.0001 to 1 w / w. %, More preferably 0.001 to 0.2 w / w%.
  • IU international unit
  • the pressure is about 10000 to 200,000 IU.
  • the amount is preferably about 0.00001 to 70% by weight (w / w) based on the entire composition.
  • the blending amount may be small, for example, 0.000001 to 30 w / w%, more preferably 0.00001 to 5 w / w%, still more preferably 0.00001 to 0.3 w. / w%.
  • the blending ratio of the component (B) to the component (A) is not particularly limited as long as the effects of the present invention can be achieved, but usually the total amount of the component (A) is 1 part by weight, The total amount of component (B) is preferably about 0.2 to 300,000 parts by weight.
  • each vitamin will be described in detail.
  • the component (B) is a fat-soluble vitamin such as vitamin A or vitamin E:
  • the total amount of the component (A) is 1 part by weight, and the total amount of the component (B) is 0.2 to 50000 parts by weight.
  • the amount is preferably 2 to 5000 parts by weight, more preferably 20 to 3000 parts by weight.
  • the total amount of component (A) is usually about 6000 to 200 million IU, preferably about 10000 to 50000000 IU, more preferably 20000 to 1 mg per 1 mg. It is preferable to set it to about 20000000 IU, more preferably about 200,000 to 10000000 IU.
  • the component (B) is a water-soluble vitamin such as vitamin C or pyrroloquinoline quinone:
  • the total amount of the component (A) is 1 part by weight, and the total amount of the component (B) is 0.5 to 300,000 parts by weight.
  • the amount is preferably 0.5 to 100,000 parts by weight, more preferably 0.5 to 10,000 parts by weight, and more preferably 0.5 to 5000 parts by weight.
  • the composition of the present invention containing the component (A) and the component (B) can promote adhesion between cells and collagen.
  • the cell is a skin cell, more preferably a fibroblast.
  • Various types of collagen such as types I to XIX have been known so far, and any type of collagen is also known.
  • the composition of the present invention can be used for adhesion between type I collagen (collagen type I) and fibroblasts, which are abundant in the dermis of skin, and type IV collagen (collagen type IV), which is abundant in the basement membrane of skin. Can promote adhesion between keratinocytes and keratinocytes.
  • the composition of the present invention is also beneficial for improving skin wrinkles and tarmi caused by a decrease in the adhesion ability between the fibroblasts and collagen, or for restoring skin firmness and elasticity. Can be used.
  • the turnover means that keratinocytes of the epidermis are produced in the basal layer of the skin, form a horny layer, and finally fall off in the skin. Skin cells are reborn as a new cell by turnover. The turnover time is shortened by promoting the turnover.
  • the composition of the present invention is also beneficially used to improve talmi, wrinkles, reduced turnover, spots, dullness, and thinning of the epidermis due to reduced adhesion ability between keratinocytes and collagen. obtain.
  • the promotion of adhesion between cells and collagen can be achieved, for example, by culturing cells using a culture medium containing the hydrolyzate in a culture plate coated with collagen, washing the plate, The number of cells remaining in the collagen coat can be measured by measuring the number of cells remaining in the collagen coat, and the number of cells remaining in the collagen coat is significantly different from the case where the components (A) and (B) are not added. When the number increases, it can be determined that adhesion between each cell and collagen is promoted.
  • a person skilled in the art will be able to enhance the bond between fibroblasts and the extracellular matrix and increase the tensile strength of both to enhance the dermis. It can be understood that it has the effect of tightening, improving skin wrinkles and sagging, or restoring the elasticity and elasticity of the skin.
  • such compositions enhance the adhesion between epidermal keratinocytes and the basement membrane to improve sagging (eg, sagging pores) and wrinkles, or promote turnover, thereby causing spots and It can also be understood that it has the effect of improving dullness and improving skin thinning.
  • the composition of the present invention is preferably a cosmetic composition. Since this composition contains the combination of (A) component and (B) component which have said function, it can have a cosmetic effect. That is, the composition of the present invention containing a combination of the component (A) and the component (B) has an effect of promoting adhesion between cells and collagen. By this action, the skin can be tightened to improve the wrinkles and talmi of the skin, or to restore the firmness and elasticity of the skin, and the turnover failure and the accompanying spots or dullness, or the epidermis Since thinning can be improved, a remarkable cosmetic effect can be achieved.
  • a composition that can be used for the purpose of making the face and body beautiful for example, beauty such as beautiful skin
  • a beauty composition a composition that can be used for the purpose of making the face and body beautiful
  • composition of the present invention can be suitably used as a pharmaceutical composition, a cosmetic composition, a food composition or a feed composition.
  • a pharmaceutical composition a cosmetic composition, a food composition or a feed composition.
  • pharmaceutical compositions a cosmetic composition, a food compositions and feed compositions used for cosmetic purposes.
  • the composition of the present invention can be suitably used as a research reagent for elucidating physiological states related to adhesion between cells and collagen.
  • the pharmaceutical composition examples include a prophylactic and / or therapeutic agent for a disease caused by a decrease in adhesion ability between cells and collagen in mammals including humans.
  • the pharmaceutical composition of the present invention is, for example, a preventive agent for skin wrinkles or tarmi caused by a decrease in the ability to adhere between fibroblasts or keratinocytes and collagen caused by aging or the like and / or
  • a therapeutic agent as a prophylactic and / or therapeutic agent for skin elasticity or a decrease in elasticity due to the decrease in adhesion ability, or as a skin tightening agent, poor skin turnover due to the decrease in adhesion ability or It can be used as a prophylactic and / or therapeutic agent for accompanying stains or dullness, or as a prophylactic and / or therapeutic agent for thinning of the skin caused by the reduced adhesive ability.
  • the cosmetic composition can be used, for example, as a cosmetic for preventing and / or improving a state caused by a decrease in the adhesion ability between cells and collagen in mammals including humans.
  • the cosmetic composition of the present invention can prevent and / or prevent wrinkles or talmi of the skin caused by, for example, a decrease in the adhesion ability between fibroblasts or keratinocytes caused by aging and the like and collagen.
  • the adhesive ability As a cosmetic for improvement, as a cosmetic for preventing and / or improving skin elasticity or a decrease in elasticity due to a decrease in the adhesive ability, or as a cosmetic for tightening the skin, the adhesive ability As a cosmetic for the prevention and / or improvement of skin turnover failure due to deterioration and the accompanying stains or dullness, or for the prevention and / or improvement of epidermis thinning due to the reduced adhesive ability It can be used as a fee.
  • the food composition for example, it can be used as a food for preventing and / or improving a state caused by a decrease in the adhesion ability between cells and collagen in mammals including humans.
  • the food composition of the present invention prevents and / or improves skin wrinkles or talmi caused by, for example, a decrease in the adhesion ability between fibroblasts or keratinocytes and collagen caused by aging or the like.
  • the food composition of the present invention includes health food, food for specified health use, nutritional functional food, health supplement food, and the like. These compositions include cosmetic health foods.
  • the food for specified health is a food that is ingested for the purpose of specific health in the diet, and indicates that the purpose of the health can be expected by the intake.
  • These food products can be provided as food products with a label indicating that they are used for the above-mentioned purposes in a specific embodiment. In other words, it is used to display the indication that it is used for beauty, the indication that it has a beautifying effect, the indication that it is used for improving the skin quality, and to restore the elasticity and elasticity of the skin.
  • An indication that it is used an indication that it is used for prevention or improvement of skin wrinkles and talmi, an indication that it is used for tightening the skin, poor skin turnover, and It can be provided as a food with a label indicating that it is used for the prevention or improvement of accompanying stains or dullness, or a label indicating that it is used for the prevention or improvement of skin thinning .
  • feed for example, for the prevention and / or improvement of conditions caused by reduced adhesion between cells and collagen in livestock such as cattle, pigs, chickens, sheep and horses, and pet animals such as dogs and cats Feed.
  • composition of the present invention includes carriers, bases, and / or additives that are usually used in fields such as the pharmaceutical field and food field. In the range which achieves, it can mix
  • saccharides for example, saccharides, celluloses, poorly water-soluble gums, crosslinked vinyl polymers, lipids and the like can be used alone or in combination.
  • water, fats and oils, mineral oils, waxes, fatty acids, silicone oils, sterols, esters, metal soaps, alcohols and the like may be used alone or in combination of two or more.
  • additives include surfactants, solubilizing components, emulsifiers, oils, stabilizers, thickeners, preservatives, binders, lubricants, dispersants, pH adjusters, humectants, UV absorbers.
  • Chelating agents, percutaneous absorption enhancers, antioxidants, disintegrating agents, plasticizers, buffering agents, amino acids, coloring agents, fragrances and the like may be used alone or in combination.
  • the composition of the present invention includes a whitening component, an anti-inflammatory component, an antibacterial component, a cell activation component, an astringent component, an antioxidant component, an acne improving component, Various components such as a biocomponent synthesis promoting component such as collagen, a blood circulation promoting component, a moisturizing component, and an anti-aging component may be used alone or in combination.
  • composition of the present invention may be in any dosage form such as an internal preparation (including food and feed) or an external preparation (including cosmetics).
  • the hydrolyzate can be appropriately blended by a method known to those skilled in the art depending on the properties of the target food.
  • the external preparation for example, it can be used in any form such as liquid, emulsion, cream, lotion, paste, mousse, gel, sheet (supported substrate), aerosol, and spray.
  • Cosmetics include, for example, basic cosmetics such as lotions, emulsions, creams, oils, packs, makeup cosmetics such as foundations, blushers and lipsticks, as well as cleansers such as facial cleansers, cleansings, body cleansers, and bath preparations. Etc. may be used in any form.
  • the feed is not particularly limited because it can be used in any form.
  • the present invention further includes a method for promoting adhesion between cells and collagen, a method for tightening skin, a wrinkle on skin, a talmi, a firmness, characterized in that the component (A) and the component (B) are used in combination.
  • a method for improving or preventing a decrease, elasticity decrease, turnover failure, spot, dullness, or thinning of the skin or a cosmetic method. In such a method, it is better to apply to the subject in the form of a composition containing the component (A) and the component (B) more simply.
  • the component (A) and the component (B) may be used in an amount that is greater than or equal to an effective amount that provides an effect of promoting adhesion between cells and collagen.
  • the amount of the composition used in the method of the present invention is usually about 0.001 to 10000 mg / day, more preferably about 1 to 1000 mg / day per adult body weight of about 50 kg in the case of internal use. Day, more preferably about 1-100 mg / day. In the case of an external preparation, the amount used is usually about 0.1 ⁇ g to 2 g / day per adult weight of about 50 kg.
  • the amount of the composition applied to the skin is preferably about 1 ng to 500 ⁇ g / cm 2 , more preferably about 0.01 to 50 ⁇ g / cm 2 , and still more preferably about 0.1 to 10 ⁇ g / cm 2 . is there.
  • the present invention further provides skin wrinkles, sagging, firmness reduction, elasticity for the manufacture of a composition for tightening the skin, for the manufacture of a composition for promoting adhesion between cells and collagen.
  • the usage amount of the component (A) and the component (B) may be used so as to be the content in the composition.
  • Example 1 Preparation of DLDVF (Asp-Leu-Asp-Val-Phe) peptide: Peptide synthesis: The title peptide was synthesized by a solid phase synthesis method using the Fmoc method using an automatic peptide synthesizer (manufactured by Shimadzu Corporation: PSSM8). The specific procedure is as follows: First, the C-terminus of Fmoc-Phe (1-Trt) -OH is bound to the resin for solid phase synthesis, and then the protecting group (Fmoc) is removed by piperidine treatment, and then After neutralizing and washing this resin, Fmoc-Val-OH was introduced into the N-terminus of Phe.
  • PSSM8 automatic peptide synthesizer
  • the protecting group (Fmoc) was removed by piperidine treatment, the resin was neutralized and washed again, and Fmoc-Asp (OtBu) -OH was introduced into the N-terminus of Val.
  • the protecting group (Fmoc) was removed by piperidine treatment, the resin was neutralized and washed again, and Fmoc-Leu-OH was introduced into the N-terminus of Asp.
  • the protecting group (Fmoc) was removed by piperidine treatment, and this resin was neutralized and washed again, and Fmoc-Asp (OtBu) -OH was introduced into the N-terminus of Leu.
  • Example 2 Preparation of RDLDV (Arg-Asp-Leu-Asp-Val) peptide: Peptide synthesis: The title peptide was synthesized by a solid phase synthesis method by Fmoc method using an automatic peptide synthesizer (manufactured by Shimadzu Corporation: PSSM8). The specific procedure is as follows: First, the C-terminus of Fmoc-Val (1-Trt) -OH is bound to the resin for solid phase synthesis, and then the protecting group (Fmoc) is removed by piperidine treatment, and then After neutralizing and washing the resin, Fmoc-Asp (OtBu) -OH was introduced into the N terminus of Val.
  • Fmoc-Asp (OtBu) -OH was introduced into the N terminus of Val.
  • the protecting group (Fmoc) was removed by piperidine treatment, the resin was neutralized and washed again, and Fmoc-Leu-OH was introduced into the N-terminus of Asp.
  • the protecting group (Fmoc) was removed by piperidine treatment, the resin was neutralized and washed again, and Fmoc-Asp (OtBu) -OH was introduced into the N-terminus of Leu.
  • the protecting group (Fmoc) was removed by piperidine treatment, the resin was neutralized and washed again, and Fmoc-Arg (Pmc) -OH was introduced into the N-terminus of Asp.
  • Example 3 Evaluation of cell adhesion to collagen coat (1) Using the DLDVF peptide prepared in Example 1 above and various vitamins (vitamin A, vitamin E, vitamin C, and pyrroloquinoline quinones), the effect of promoting the adhesion of fibroblasts to the collagen coat Evaluation was performed.
  • Example 4 Evaluation of cell adhesion to collagen coat (2) Using the RDLDV peptide prepared in Example 2 above and various vitamins (vitamin A, vitamin E, vitamin C, and pyrroloquinoline quinone), the effect of promoting the adhesion of fibroblasts to the collagen coat Evaluation was performed.
  • the test method was substantially the same as Example 3 except that the peptides used in the test were different.
  • Example 3 only the cell adhesion rate and vitamins of the group (combination group) used in combination with vitamins when the cell adhesion rate in the control group (that is, the test peptide alone group) is 100 are added.
  • the cell adhesion rate of the obtained group (single group) was calculated. The results are shown in Table 2 below.
  • each vitamin can be obtained by using it together with each vitamin such as vitamin A, vitamin E, vitamin C, or pyrroloquinoline quinone. It was revealed that the cell adhesion rate can be effectively increased as compared with the case of containing a kind alone.
  • Example 5 Evaluation of cell adhesion to collagen coat (3) Using the DLDVF peptide and RDLDV peptide prepared in Examples 1 and 2 and vitamins E ( ⁇ -tocopherol), the effect of promoting adhesion of fibroblasts to the collagen coat was further evaluated.
  • the test method was carried out in substantially the same manner as in Example 3 except that the types of components used in the test and the concentration added to the medium were different.
  • the results are shown in Table 3 below.
  • Example 6 Evaluation of cell adhesion to collagen coat (4) Using the DLDVF peptide and RDLDV peptide prepared in Examples 1 and 2 and various vitamin Cs (3-O-ethylascorbic acid, sodium ascorbyl phosphate) to promote the adhesion of fibroblasts to the collagen coat Further evaluation was performed.
  • the test method was carried out in substantially the same manner as in Example 3 except that the types of components used in the test and the concentration added to the medium were different.
  • Example 7 Evaluation of cell adhesion to collagen coat (5) Using the DLDVF peptide and RDLDV peptide prepared in Examples 1 and 2 and various vitamins (vitamin Es and vitamins C), the effect of promoting the adhesion of fibroblasts to the collagen coat was further evaluated.
  • the test method was carried out in substantially the same manner as in Example 3 except that the types of components used in the test and the concentration added to the medium were different.
  • Example 8 Evaluation of cell adhesion to collagen coat (6) Using DLDVF peptide and RDLDV peptide prepared in Examples 1 and 2 and various vitamins (vitamin A, pyrroloquinoline quinone, vitamin-like agent), the effect of promoting the adhesion of fibroblasts to the collagen coat Further evaluation was performed.
  • the test method was carried out in substantially the same manner as in Example 3 except that the types of components used in the test and the concentration added to the medium were different.
  • the DLDVF peptide or RDLDV peptide and various vitamins increases the cell adhesion rate more effectively than when various vitamins are used alone.
  • vitamin A retinol
  • pyrroloquinoline quinone pyrroloquinoline quinone
  • vitamin-like agent ⁇ -It has been found that the combined use of lipoic acid and coenzyme Q10)
  • composition containing the specific peptides and vitamins of the present invention can promote adhesion between cells and collagen, the skin is tightened to improve skin wrinkles and tarmi, and the skin is firm and elastic. In addition, it is possible to restore the skin, improve the turnover failure and the accompanying stain or dullness, improve the thinning of the epidermis, and can be beneficially used for beauty.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a pour objet une nouvelle composition capable de favoriser l'adhésion entre une cellule et le collagène, de raffermir la peau, qui aide ainsi à réduire les rides et le relâchement de la peau et/ou à améliorer la récupération de la tension ou de l'élasticité de la peau, ou analogues, et pouvant contribuer à améliorer le faible renouvellement, et les imperfections, l'aspect terne de la peau, ou l'amincissement de l'épiderme qui sont associés au faible renouvellement, et peut par conséquent être utilisé avec efficacité dans pour applications cosmétiques. L'invention porte sur une composition qui contient (A) un peptide comprenant une séquence d'acides aminés représentée par la formule (I) : Xaa1-Asp-Leu-Asp-Val-Xaa2 (SEQ ID NO: 1) [dans laquelle Xaa1 et Xaa2 peuvent être présents ou non et, s'ils sont présents représentent indépendamment l'un de l'autre un résidu arbitraire d'acide aminé], un dérivé dudit peptide ou un sel de ce peptide ou de son dérivé, et (B) une vitamine.
PCT/JP2012/083196 2011-12-22 2012-12-21 Composition présentant une activité promotrice de l'adhésion cellulaire Ceased WO2013094720A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-281276 2011-12-22
JP2011281276 2011-12-22

Publications (1)

Publication Number Publication Date
WO2013094720A1 true WO2013094720A1 (fr) 2013-06-27

Family

ID=48668598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/083196 Ceased WO2013094720A1 (fr) 2011-12-22 2012-12-21 Composition présentant une activité promotrice de l'adhésion cellulaire

Country Status (1)

Country Link
WO (1) WO2013094720A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500673A (ja) * 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
WO2007148837A1 (fr) * 2006-06-23 2007-12-27 Rohto Pharmaceutical Co., Ltd. Composition capable de favoriser la production de collagène
US7402407B1 (en) * 2003-10-03 2008-07-22 California Institute Of Technology Chemically targeted positional identification of post-translationally phosphorylated peptides
JP2011504894A (ja) * 2007-11-30 2011-02-17 エヴォニク ゴールドシュミット ゲーエムベーハー モチーフｇｘ１ｘ２ｇ、ｐｘ１ｘ２ｐ、またはｐｘ１ｘ２ｋを有するテトラペプチドを含有するパーソナルケアおよび化粧品組成物
JP2011201872A (ja) * 2010-03-09 2011-10-13 Lvmh Recherche 蜂蜜及びペプチドの組み合わせを含む化粧用又は皮膚科用組成物
WO2012144546A1 (fr) * 2011-04-22 2012-10-26 ロート製薬株式会社 Nouveau peptide

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500673A (ja) * 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US7402407B1 (en) * 2003-10-03 2008-07-22 California Institute Of Technology Chemically targeted positional identification of post-translationally phosphorylated peptides
WO2007148837A1 (fr) * 2006-06-23 2007-12-27 Rohto Pharmaceutical Co., Ltd. Composition capable de favoriser la production de collagène
JP2011504894A (ja) * 2007-11-30 2011-02-17 エヴォニク ゴールドシュミット ゲーエムベーハー モチーフｇｘ１ｘ２ｇ、ｐｘ１ｘ２ｐ、またはｐｘ１ｘ２ｋを有するテトラペプチドを含有するパーソナルケアおよび化粧品組成物
JP2011201872A (ja) * 2010-03-09 2011-10-13 Lvmh Recherche 蜂蜜及びペプチドの組み合わせを含む化粧用又は皮膚科用組成物
WO2012144546A1 (fr) * 2011-04-22 2012-10-26 ロート製薬株式会社 Nouveau peptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HASHIMOTO, Y. ET AL.: "Identification of an Autoinhibitory Domain in Calcineurin", J. BIOL. CHEM., vol. 265, no. 4, 1990, pages 1924 - 1927 *

Similar Documents

Publication Publication Date Title
JP2010024200A (ja) 生体コラーゲン合成促進剤並びに生体コラーゲン合成促進用飲食品、化粧品及び医薬部外品
KR20190101990A (ko) 펩티드 wkdeagkplvk를 포함하는 조성물
JP2008156330A (ja) 賦活化剤及び抗老化剤
US7989590B2 (en) Peptides that increase collagen or hyaluronic acid production
JP5890100B2 (ja) 皮膚コラーゲン産生促進剤
JP6336781B2 (ja) 新規ペプチド
WO2007148803A1 (fr) Composition capable de favoriser la production d'acide hyaluronique
CN103747793A (zh) 含有大豆蛋白质的水解物的组合物
JP2008239548A (ja) 細胞賦活化剤
JP2008239549A (ja) 細胞外マトリックス産生向上剤
JP2018039751A (ja) 表皮細胞間機能強化剤
JP2004331566A (ja) 皮膚コラーゲン産生促進剤
JP5123683B2 (ja) 新規ペプチド
KR101305274B1 (ko) 콜라겐 합성 촉진용 조성물
KR101218898B1 (ko) 콜라겐 합성 촉진용 조성물
WO2013129456A1 (fr) Composition capable de promouvoir la prolifération de fibroblastes
JP2008074788A (ja) エラスチン産生促進剤
CN103443118B (zh) 新型肽
WO2013094720A1 (fr) Composition présentant une activité promotrice de l'adhésion cellulaire
JP2009155305A (ja) 新規ペプチド
JP4439510B2 (ja) 新規ペプチド
CN104072582B (zh) 新型肽
WO2015111857A1 (fr) Dérivé peptidique et composition cosmétique fonctionnelle contenant ce dernier
JP2009184984A (ja) 新規ペプチド
HK1187628B (en) Novel peptide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12858949

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12858949

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP